Dewpoint Therapeutics
PrivateLast Round
Series D
Sep 10, 2025
Total Funding Raised
$346.1M
Company Overview
Dewpoint Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series D round in September 2025.
Dewpoint Therapeutics is a biotechnology company that develops small molecule medicines targeting biomolecular condensates to treat intractable conditions including cancer, neurodegeneration, and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dewpoint Therapeutics Comparables
Compare Dewpoint Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Transition Bio | 88% | |
| Nereid Therapeutics | 84% | |
| ETERN Therapeutics | 84% |
For institutional investors. Book with your work email.
Dewpoint Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 10, 2025 | ||||
| Series B | Sep 9, 2025 | ||||
| Series C | Feb 3, 2022 | ||||
| Series B | Sep 29, 2020 | ||||
| Series A | Jan 30, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Dewpoint Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series C, Series B, Series A |
| SoftBank Investment Advisers | Series C |
| Maverick Ventures | Series C, Series A, Series B |
| Bencao Capital | Series C |
| Innovation Endeavors | Series B |
| SoftBank Group | Series C |
| Bellco Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Presented preclinical data on Oral MYC condensate modulator at AACR 2026.
- Apr 21, 2026
Presented data at the AACR 2026 conference.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 15, 2026
Dewpoint Therapeutics, Inc. appoints Corey Anderson as Executive Director, Head of Chemistry to lead its chemistry function and support the translation of its TAL-based drug discovery platform into medicines.
- hiresAug 26, 2026
Dewpoint Therapeutics, Inc. hires William Senapedis as Head of Late Discovery & Translational on Aug 26th '26, as it advances its pipeline of condensate-modulating therapies.
For institutional investors. Book with your work email.
Dewpoint Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Dewpoint Therapeutics's valuation, stock price, and market status.
Is Dewpoint Therapeutics a public or private company?
Dewpoint Therapeutics is a private company.
What is the current stock price of Dewpoint Therapeutics?
Dewpoint Therapeutics is a private company, so its shares have no public market price. Caplight tracks Dewpoint Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Dewpoint Therapeutics worth (valuation)?
Valuation information for Dewpoint Therapeutics is not publicly available.
Can I buy Dewpoint Therapeutics stock?
Dewpoint Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Dewpoint Therapeutics's last funding round?
Dewpoint Therapeutics's most recent funding round was Series D on September 10, 2025.
Who are the main investors in Dewpoint Therapeutics?
Key investors in Dewpoint Therapeutics include SoftBank Investment Advisers, Maverick Ventures, SoftBank Group, ARCH Venture Partners, Polaris Partners.
Will Dewpoint Therapeutics IPO soon?
No public IPO plans have been announced for Dewpoint Therapeutics.
How can I track Dewpoint Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Dewpoint Therapeutics's shares on secondary markets.